
Atrium Therapeutics, Inc.: shareholders and insiders
Price
$6.92
November 20, 2026Market cap $149M
Insiders and their shares
Purchases and sales by officers and directors from Sep 18, 2026 to Sep 22, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
–
nobody
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
- Sep 18, 2026Husam YounisChief Scientific OfficerKind
- Sep 18, 2026Steven George HughesChief Medical OfficerKind
- Sep 18, 2026W. Michael FlanaganDirectorKind
- Sep 18, 2026Sarah BoyceDirectorKind
- Sep 18, 2026Stephanie KenneyChief Corporate Affairs OfficerKind
- Sep 18, 2026Kathleen P. GallagherChief Executive Officer and PresidentKind
- Sep 18, 2026Brendan R. WinslowChief Financial OfficerKind
- Sep 18, 2026Rocio Martin HoyosChief Strategy OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Husam YounisChief Scientific Officer | 11.2K | $8.95 | $100.4K | Form 4 | |
| Sep 18, 2026 | Steven George HughesChief Medical Officer | 21.5K | $8.95 | $192.1K | Form 4 | |
| Sep 18, 2026 | W. Michael FlanaganDirector | 22.8K | $8.95 | $204.2K | Form 4 | |
| Sep 18, 2026 | Sarah BoyceDirector | 126.4K | $8.95 | $1.1M | Form 4 | |
| Sep 18, 2026 | Stephanie KenneyChief Corporate Affairs Officer | 2,375 | $8.95 | $21.3K | Form 4 | |
| Sep 18, 2026 | Kathleen P. GallagherChief Executive Officer and President | 11.6K | $8.95 | $104.1K | Form 4 | |
| Sep 18, 2026 | Brendan R. WinslowChief Financial Officer | 6,742 | $8.95 | $60.3K | Form 4 | |
| Sep 18, 2026 | Rocio Martin HoyosChief Strategy Officer | 8,320 | $8.95 | $74.5K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Sessa Capital IM, L.P.with 1 more personShare of class8.80%
- T. Rowe Price Associates, Inc.Share of class8.60%
- BlackRock, Inc.Share of class6.60%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Sessa Capital IM, L.P.with 1 more person | 8.80% | 1.50M | Aug 14, 2026 | 13G | |
| T. Rowe Price Associates, Inc. | 8.60% | 1.47M | Aug 14, 20262 filings since Apr 8, 2026 | 13G/A | |
| BlackRock, Inc. | 6.60% | 1.14M | Jul 27, 20262 filings since Apr 27, 2026 | 13G/A |
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- RA Capital Management, L.P.0.00%Aug 14, 202613G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter+223%
- Millennium Mgmt (Englander)In the quarter-26%
- Renaissance TechnologiesIn the quarter+58%
- AQR CapitalIn the quarter-82%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 28.9K | $200.0K | 0.00% | |
| Citadel Advisors (Griffin) | 218.4K | +223% | $1.8M | 0.00% |
| Millennium Mgmt (Englander) | 147.7K | -26% | $1.2M | 0.00% |
| Renaissance Technologies | 23.7K | +58% | $200.0K | 0.00% |
| AQR Capital | 31.0K | -82% | $300.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 3.73M shares were held short, +9.7% since the report before.
- Shares held short
- 3.73M
- Since the report before3.40M on Sep 30, 2026
- +9.7%
- 12.9
- 288.0K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 96%
- Report date
- Oct 15, 2026
- Shares held short
- Feb 27, 2026: Shares held short 432.8K
- Mar 13, 2026: Shares held short 1.18M
- Mar 31, 2026: Shares held short 1.91M
- Apr 15, 2026: Shares held short 3.02M
- Apr 30, 2026: Shares held short 3.43M
- May 15, 2026: Shares held short 3.73M
- May 29, 2026: Shares held short 3.65M
- Jun 15, 2026: Shares held short 3.61M
- Jun 30, 2026: Shares held short 3.66M
- Jul 15, 2026: Shares held short 3.59M
- Jul 31, 2026: Shares held short 3.51M
- Aug 14, 2026: Shares held short 3.48M
- Aug 31, 2026: Shares held short 3.35M
- Sep 15, 2026: Shares held short 3.40M
- Sep 30, 2026: Shares held short 3.40M
- Oct 15, 2026: Shares held short 3.73M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading45.9% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 45.9% of the shares in the reported trades were short sales, against 38.6% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 45.9%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 38.6%
- Change
- +7.3 pts
- Short sales a dayon average, of 81.8K shares
- 37.5K
- More than atof 3,666 US-listed companies, same days
- 35%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 66.5%
- Oct 15, 2026: Short sales 60.4%
- Oct 16, 2026: Short sales 53.1%
- Oct 19, 2026: Short sales 28%
- Oct 20, 2026: Short sales 33.2%
- Oct 21, 2026: Short sales 39.2%
- Oct 22, 2026: Short sales 39.5%
- Oct 23, 2026: Short sales 50.5%
- Oct 26, 2026: Short sales 49.1%
- Oct 27, 2026: Short sales 36.5%
- Oct 28, 2026: Short sales 21.2%
- Oct 29, 2026: Short sales 33.4%
- Oct 30, 2026: Short sales 15.6%
- Nov 2, 2026: Short sales 62.1%
- Nov 3, 2026: Short sales 46.5%
- Nov 4, 2026: Short sales 26.8%
- Nov 5, 2026: Short sales 46.7%
- Nov 6, 2026: Short sales 25.1%
- Nov 9, 2026: Short sales 25.5%
- Nov 10, 2026: Short sales 33%
- Nov 11, 2026: Short sales 21.8%
- Nov 12, 2026: Short sales 59.5%
- Nov 13, 2026: Short sales 42.9%
- Nov 16, 2026: Short sales 31.5%
- Nov 17, 2026: Short sales 48.6%
- Nov 18, 2026: Short sales 65.6%
- Nov 19, 2026: Short sales 47.6%
- Nov 20, 2026: Short sales 62.5%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Sarah BoyceDirectorDirectly138.7K
- Kathleen P. GallagherChief Executive Officer and PresidentDirectly119.7K
- Steven George HughesChief Medical OfficerDirectly51.6K
- Husam YounisChief Scientific OfficerDirectly41.4K
- Rocio Martin HoyosChief Strategy OfficerDirectly38.3K
- Brendan R. WinslowChief Financial OfficerDirectly36.9K
- Stephanie KenneyChief Corporate Affairs OfficerDirectly33.1K
- W. Michael FlanaganDirectorDirectly32.0K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Sarah BoyceDirector | 138.7K | – | Sep 18, 2026 | Form 4 |
| Kathleen P. GallagherChief Executive Officer and President | 119.7K | – | Sep 18, 2026 | Form 4 |
| Steven George HughesChief Medical Officer | 51.6K | – | Sep 18, 2026 | Form 4 |
| Husam YounisChief Scientific Officer | 41.4K | – | Sep 18, 2026 | Form 4 |
| Rocio Martin HoyosChief Strategy Officer | 38.3K | – | Sep 18, 2026 | Form 4 |
| Brendan R. WinslowChief Financial Officer | 36.9K | – | Sep 18, 2026 | Form 4 |
| Stephanie KenneyChief Corporate Affairs Officer | 33.1K | – | Sep 18, 2026 | Form 4 |
| W. Michael FlanaganDirector | 32.0K | – | Sep 18, 2026 | Form 4 |
A lower bound: it counts only the 8 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.04%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.00%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.00%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.00%
- AVUSAvantis U.S. Equity ETFWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
16 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 274
- Q4 2025: Managers 345
- Q1 2026: Managers 167
- Q2 2026: Managers 156
Institutional investors by quarter
The fund managers holding RNA, quarter by quarter, from Q2 2013 to Q2 2025, 28 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 156 managers held 15.49M shares, worth $208M. During the quarter 40 opened a position, 48 closed one, 44 added and 36 trimmed.
The largest holders, Q2 2026
- Sessa Capital IMIn the quarter+172%
- Price T Rowe AssociatesIn the quarter-5.2%
- BlackRockIn the quarter+20%
- CrcmIn the quarter
- Vanguard Capital ManagementIn the quarter+17%
- TIG AdvisorsIn the quarter-7.6%
- Arbiter Partners Capital ManagementIn the quarter+127%
- Cantor Fitzgerald, L. P.In the quarter+118%
- Geode Capital ManagementIn the quarter+21%
- Two Sigma InvestmentsIn the quarter+93%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Sessa Capital IM | 1.50M | +172% | $20M |
| Price T Rowe Associates | 1.47M | -5.2% | $20M |
| BlackRock | 1.45M | +20% | $19M |
| Crcm | 1.28M | $17M | |
| Vanguard Capital Management | 730.8K | +17% | $9.8M |
| TIG Advisors | 561.5K | -7.6% | $7.6M |
| Arbiter Partners Capital Management | 522.6K | +127% | $7.0M |
| Cantor Fitzgerald, L. P. | 513.8K | +118% | $6.9M |
| Geode Capital Management | 386.9K | +21% | $5.2M |
| Two Sigma Investments | 345.5K | +93% | $4.6M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
Have RNA's insiders bought or sold?
From Sep 22, 2026 to Sep 22, 2026 Atrium Therapeutics's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold RNA?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $1.8M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.